Catalyst Wire Dossier Catalyst Wire Dossier

Sac-TMT (MK-2870)

sacituzumab tirumotecan · Merck & Co.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Sac-TMT (MK-2870), covering 2026-04-02 to 2026-04-02. Get the full timeline:

Most recent: Clinical Trial Update: Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] [Phase 3]

See pricing